Literature DB >> 17309951

Inhibition of intrinsic interferon-gamma function prevents neointima formation after balloon injury.

Ken Kusaba1, Hisashi Kai, Mitsuhisa Koga, Narimasa Takayama, Ayami Ikeda, Hideo Yasukawa, Yukihiko Seki, Kensuke Egashira, Tsutomu Imaizumi.   

Abstract

It is still controversial whether intrinsic interferon (IFN)-gamma promotes or attenuates vascular remodeling in hyperproliferative vascular disorders, such as neointima formation after balloon injury. Thus, we investigated whether inhibition of intrinsic IFN-gamma function prevents neointima formation. For this purpose, naked DNA plasmid encoding a soluble mutant of IFN-gamma receptor alpha-subunit (sIFNgammaR; an IFN-gamma inhibitory protein) or mock plasmid was injected into the thigh muscle of male Wistar rats 2 days before balloon injury (day -2). sIFNgammaR gene transfer significantly elevated serum levels of sIFNgammaR protein for 2 weeks. In mock-treated rats, balloon injury induced smooth muscle cell proliferation in the neointima with a peak at day 7 and produced thick neointima at day 14. sIFNgammaR treatment reduced the number of proliferating intimal smooth muscle cells by 50% at day 7 and attenuated neointima formation with a 45% reduction of the intima/media area ratio at day 14. In mock-treated rats, at day 7, balloon injury induced phosphorylation of signal transducer and activator of transcription-1 and upregulations of IFN regulatory factor-1 (a transcription factor mediating IFN-gamma signal). Balloon injury also upregulated the key molecules of neointima formation, such as intercellular adhesion molecule-1 and platelet-derived growth factor beta-receptor. These changes were suppressed by sIFNgammaR treatment. In conclusion, it is suggested that intrinsic IFN-gamma promotes neointima formation probably through IFN regulatory factor-1/intercellular adhesion molecule-1-mediated and platelet-derived growth factor-mediated mechanisms. Thus, inhibition of IFN-gamma signaling may be a new therapeutic target for prevention of neointima formation of hyperproliferative vascular disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309951     DOI: 10.1161/01.HYP.0000259668.37901.8c

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Axl modulates immune activation of smooth muscle cells in vein graft remodeling.

Authors:  Sri N Batchu; Jixiang Xia; Kyung Ae Ko; Marvin M Doyley; Jun-Ichi Abe; Craig N Morrell; Vyacheslav A Korshunov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-14       Impact factor: 4.733

Review 2.  The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.

Authors:  Xiao-Jing Zhang; Ding-Sheng Jiang; Hongliang Li
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Exercise training decreases the size and alters the composition of the neointima in a porcine model of percutaneous transluminal coronary angioplasty (PTCA).

Authors:  Bradley S Fleenor; Douglas K Bowles
Journal:  J Appl Physiol (1985)       Date:  2009-06-25

4.  Selective gene expression analysis of muscular and vascular components in hearts using laser microdissection method.

Authors:  Ayami Ikeda; Hisashi Kai; Hidemi Kajimoto; Suguru Yasuoka; Masayoshi Kage; Tsutomu Imaizumi
Journal:  Int J Vasc Med       Date:  2012-06-12

5.  15-Lipoxygenase-1 Is Involved in the Effects of Atorvastatin on Endothelial Dysfunction.

Authors:  Peng Zhang; Xin Xing; Chunxiao Hu; Hui Yu; Qian Dong; Guanglei Chang; Shu Qin; Jian Liu; Dongying Zhang
Journal:  Mediators Inflamm       Date:  2016-08-10       Impact factor: 4.711

6.  Age-related changes in monocytes exacerbate neointimal hyperplasia after vascular injury.

Authors:  Laisel Martinez; Camilo Gomez; Roberto I Vazquez-Padron
Journal:  Oncotarget       Date:  2015-07-10

Review 7.  Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.

Authors:  Aleksandra Antonczyk; Bart Krist; Malgorzata Sajek; Agata Michalska; Anna Piaszyk-Borychowska; Martyna Plens-Galaska; Joanna Wesoly; Hans A R Bluyssen
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.